Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials

被引:30
|
作者
Xiang, Peng [1 ,2 ,3 ]
Guan, Di [1 ]
Du, Zhen [1 ]
Hao, Yongxiu [4 ]
Yan, Wei [1 ]
Wang, Yonghui [1 ]
Liu, Yutong [1 ]
Liu, Dan [1 ]
Ping, Hao [1 ,2 ,3 ]
机构
[1] Capital Med Univ, Beijing Tongren Hosp, Dept Urol, 1 Dongjiaomingxiang St, Beijing 100730, Peoples R China
[2] Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100730, Peoples R China
[3] Capital Med Univ, Beijing Tongren Hosp, Beijing 100730, Peoples R China
[4] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China
基金
中国国家自然科学基金;
关键词
Benign prostatic hyperplasia; Embolization; therapeutic; Lower urinary tract symptoms; Systematic review; Meta-analysis;
D O I
10.1007/s00330-020-07663-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To investigate the efficacy and safety of prostatic artery embolization (PAE) vs. transurethral resection of the prostate (TURP) in patients affected by benign prostatic hyperplasia (BPH). We also reviewed mean changes from baseline in PAE at selected follow-up points. Methods PubMed, Web of Science, and Embase were searched up to May 1, 2020. Randomized controlled trials on PAE were collected according to specific inclusion and exclusion criteria. Meta-analyses were performed using RevMan 5.3, STATA 14, and GraphPad Prism 8. Pooled patient-reported scores and functional outcomes were calculated by using a fixed or random-effect model. Results Eleven articles met our selection criteria and ten independent patient series were included in the final analysis. Pooled estimates suggested no significant difference between TURP and PAE for patient-reported outcomes including International Prostate Symptom Score (2.32 (- 0.44 to 5.09)) and quality of life (0.18 (- 0.41 to 0.77)) at 12 months. PAE was less effective regarding improvements in most functional outcomes such as maximum flow rate, prostate volume, and prostate-specific antigen. Moreover, PAE may be associated with relatively fewer complications, lower cost, and shorter hospitalization. After the PAE procedure, the overall weighted mean differences for all outcomes except sexual health scores were significantly improved from baseline during follow-up to 24 months. Conclusion PAE is non-inferior to TURP with regard to improving patient-reported outcomes, though most functional parameters undergo more changes after TURP than after PAE. Moreover, PAE can significantly continue to relieve symptoms for 24 months without causing serious complications. Key Points PAE is as effective as TURP in improving subjective symptom scores, with fewer complications and shorter hospitalization times. PAE is inferior to TURP in the improvement of most functional outcomes. Improvements due to PAE are durable during follow-up to 24 months.
引用
收藏
页码:4929 / 4946
页数:18
相关论文
共 50 条
  • [41] Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis
    Luca Cindolo
    Mario Alvarez-Maestro
    Roberto Castellucci
    Luigi Schips
    World Journal of Urology, 2015, 33 : 441 - 442
  • [42] Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis
    Cindolo, Luca
    Alvarez-Maestro, Mario
    Castellucci, Roberto
    Schips, Luigi
    WORLD JOURNAL OF UROLOGY, 2015, 33 (03) : 441 - 442
  • [43] Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis
    Park, Taehwan
    Choi, Jae-Young
    WORLD JOURNAL OF UROLOGY, 2014, 32 (04) : 1093 - 1105
  • [44] Meta-Analysis of Prostatic Artery Embolization for Benign Prostatic Hyperplasia Review of 12-Month Outcomes Data response
    Uflacker, Andre
    Patrie, James
    Haskal, Ziv J.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2017, 28 (05) : 772 - 773
  • [45] Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis
    Zhou, Zhongbao
    Gao, Zhenli
    Wu, Jitao
    Cui, Yuanshan
    WORLD JOURNAL OF UROLOGY, 2020, 38 (08) : 2069 - 2070
  • [46] Prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH): efficacy and safety at 1 year
    Chiu, P. K.
    Kwok, K. Y.
    Yee, C. H.
    Teoh, J. Y.
    Sy, L. I.
    Kwok, S. W.
    Cho, C. C. M.
    Hung, E. H. Y.
    Ng, C. F.
    Yu, S. C. H.
    BJU INTERNATIONAL, 2019, 123 : 5 - 5
  • [47] The Efficacy and Safety of Holmium Laser Enucleation of Prostate Compared With Bipolar Technologies in Treating Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials
    Che, Xuanyan
    Zhou, Zhongbao
    Chai, Yumeng
    Cui, Yuanshan
    Zhang, Yong
    AMERICAN JOURNAL OF MENS HEALTH, 2022, 16 (06)
  • [48] Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis
    Zhongbao Zhou
    Zhenli Gao
    Jitao Wu
    Yuanshan Cui
    World Journal of Urology, 2020, 38 : 2069 - 2070
  • [49] Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis
    Jiang, Yu-Li
    Qian, Lu-Jie
    BMC UROLOGY, 2019, 19 (1)
  • [50] Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis
    Yu-Li Jiang
    Lu-Jie Qian
    BMC Urology, 19